Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpoint.
Robert
Nicholas J
NJ
Fairfax Northern VA, Fairfax, VA, USA. nicholas.robert@usoncology.com
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D015201:Meta-Analysis as Topic; D009362:Neoplasm Metastasis; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012107:Research Design; D016019:Survival Analysis
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab